Class 'A' Ordinary Shares

Trinity Biotech plc

IDA BUSINESS PARK, BRAY, CO WICKLOW, L2, A98 H5C8

Item 2(a) of the Original Schedule 13D is hereby amended and restated in full as follows: This Amendment No. 4 is being filed jointly by Mainstream Holdings, Ltd., a limited company incorporated in South Korea ("Mainsream Holdings"), Mainstream New Growth No. 1 Private Equity Fund, a private equity fund incorporated in South Korea ("Mainstream New Growth"), New Main Equity Co., Ltd, a limited company incorporated in South Korea ("New Main Equity"), and Kim Chang-hee (collectively, the "New Main Equity Persons"). Mainstream New Growth owns all of the equity interests in Mainstream Holdings, and New Main Equity is the general partner of Mainstream New Growth. Mr. Chang-hee serves as the managing director of Mainstream Holdings and New Main Equity.

Item 2(b) of the Original Schedule 13D is hereby amended and restated in full as follows: The address of each of the New Main Equity Persons is #11-B-05, 11F, 20, Gukjegeumyung-ro, Yeongdeungpo-gu, Seoul, Republic of Korea.

Item 2(c) of the Original Schedule 13D is hereby amended and restated in full as follows: The principal business of each of Mainstream Holdings, Mainstream New Growth, and New Main Equity is to acquire, hold and dispose of interests in various companies for investment purposes and to take all actions incident thereto. The principal occupation of Mr. Chang-hee is to serve as the managing director of Mainstream Holdings and New Main Equity.

Item 2(e) of the Original Schedule 13D is hereby amended and restated in full as follows: During the last five years, none of the New Main Equity Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 2(f) of the Original Schedule 13D is hereby amended and restated in full as follows: Each of the New Main Equity Persons was formed in or is a citizen of, as applicable, South Korea.

Item 5(a) of the Original Schedule 13D is hereby amended and restated in full as follows: The information set forth under the final paragraph of Item 4 and the cover page of this Amendment No. 4 is incorporated herein by reference into this Item 5. Following the completion of the 2024 MiCo IVD Purchase by DAYLI Holdings, the New Main Equity Persons are no longer deemed to beneficially own any Ordinary Shares.

Item 5(b) of the Original Schedule 13D is hereby amended and restated in full as follows: The information set forth under the final paragraph of Item 4 and the cover page of this Amendment No. 4 is incorporated herein by reference into this Item 5. Following the completion of the 2024 MiCo IVD Purchase by DAYLI Holdings, the New Main Equity Persons are no longer deemed to beneficially own any Ordinary Shares.

Item 5(c) of the Original Schedule 13D is hereby amended and restated in full as follows: Except as set forth in the Original Schedule 13D and this Amendment No. 4, none of the New Main Equity Persons has engaged in any transaction in Ordinary Shares during the past 60 days.

Item 5(d) of the Original Schedule 13D is hereby amended and restated in full as follows: Not Applicable.

Item 5(e) of the Original Schedule 13D is hereby amended and restated in full as follows: The 2024 MiCo IVD Purchase by DAYLI Holdings was executed on December 17, 2024 and closed on December 20, 2024, following which time the New Main Equity Persons ceased to beneficially own more than five percent of the Ordinary Shares of the Issuer.